ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue rises 40.2% from a year ago

Deferred revenue stood at $757K at the end of Q1 FY2026, up 40.2% from a year earlier and up 24.3% from the prior quarter.

Context

  • Deferred revenue amounted to 0.3% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue keeps rising in the next quarterly balance sheet after a +40.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$757K+24.3% QoQ
Last fiscal yearDec 2025
$609K+9.3% YoY
Year agoMar 2025
$540K+40.2% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.2%——
1 year+9.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
609K USD
Year-over-year change
+9.3%
4-year CAGR
-19.6%

Deferred Revenue vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's Mar 2026 deferred revenue of $757K is the 3rd highest of the 4 companies compared; the peer median is $1.09M.
  • Its year-over-year change of +40.2% is the highest of 3, against a peer median of +1.1%.
  • Deferred revenue amounts to 0.3% of total assets for SPRY, versus a peer median of 0.8%.
SPRY Competitors Peer median
Deferred Revenue for SPRY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MNKDMannKind CorporationMar 2026$11.53M -2.0%+106.8%1.5%
AQSTAquestive Therapeutics, Inc.Mar 2026$1.09M +4.2%-10.3%0.8%
SPRYARS Pharmaceuticals, Inc.Mar 2026$757K +40.2%—0.3%
XERSXeris Biopharma Holdings, Inc.Mar 2026$0 ——0.0%
Peer median (excluding SPRY) $1.09M+1.1%+48.3%0.8%

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents60.06M210.52M70.97M50.82M41.32M
Short-term Investments063.86M157.39M263.21M203.67M
Net Receivables1K0795K9.16M26.35M
Inventory0005.21M8.37M
Other Current Assets01.01M01.23M5.19M
Total Current Assets60.73M277.7M231.56M334.3M284.9M
Property, Plant & Equipment (Net)693K774K824K1.07M2.47M
Goodwill00000
Intangible Assets0007.69M14.45M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets23K2.96M801K8.11M25.84M
Total Non-current Assets716K3.74M1.63M16.86M42.76M
Total Assets61.45M281.44M233.19M351.15M327.65M
Account Payables1.79M1.66M759K9.87M5.73M
Short-term Debt3.48M0237K00
Tax Payables004K00
Deferred Revenue1.46M00557K609K
Other Current Liabilities660K1.46M1.08M2.29M588K
Total Current Liabilities8.19M5.44M2.39M23.44M39.15M
Long-term Debt4.93M00096.37M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)3M001.53M1.13M
Other Non-current Liabilities76.12M2.85M069.38M76.75M
Total Non-current Liabilities84.53M3.11M37K70.92M174.25M
Total Liabilities92.72M8.55M2.43M94.36M213.39M
Common Stock3K9K10K10K10K
Retained Earnings(42.26M)(76.94M)(131.3M)(123.31M)(294.6M)
Accumulated OCI0407K49K220K125K
Other Stockholders Equity01000
Minority Interest00000
Total Equity(31.27M)272.89M230.76M256.8M114.26M
Total Debt9.03M481K274K42K96.37M
Net Debt(51.03M)(210.04M)(70.7M)(50.78M)55.06M

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.